Key result
Phenylephrine significantly increased the risk of maternal bradycardia compared to ephedrine (OR 14.34) in pre-eclamptic patients undergoing caesarean section.
Why the study?
Spinal-induced hypotension in parturients with pre-eclampsia can cause adverse perinatal outcomes, making effective prophylaxis and treatment crucial.
Do phenylephrine, ephedrine, and norepinephrine differ in efficacy and safety for the prevention and treatment of spinal-induced hypotension in pre-eclamptic patients undergoing caesarean section?
Meta-Analysis (n=804)
Do phenylephrine, ephedrine, and norepinephrine differ in efficacy and safety for the prevention and treatment of spinal-induced hypotension in pre-eclamptic patients undergoing caesarean section?
Odds Ratio: 14.34 (95% CI 1.8–113.64)
p-value: p=0.018
Phenylephrine, ephedrine, and norepinephrine have comparable hemodynamic effects for spinal-induced hypotension in pre-eclampsia, but norepinephrine may be preferred as it improves umbilical artery pH without the increased risk of bradycardia seen with phenylephrine.
Phenylephrine increases bradycardia risk in pre-eclamptic cesarean patients; confirms comparable hemodynamics across agents while highlighting norepinephrine's favorable profile.
Background and Aims: Spinal-induced hypotension in parturients with pre-eclampsia (PE) can lead to adverse perinatal outcomes, making effective prophylaxis and treatment crucial. We aim to compare the prophylactic and therapeutic roles of phenylephrine, ephedrine, and norepinephrine (NE) in treating post-spinal hypotension in PE patients. Methods: We conducted a comprehensive search of various databases up to June 2024, focusing on randomised clinical trials (RCTs). Standardised mean differences (SMDs) were used for continuous outcomes, while odds ratios (ORs) were employed for binary outcomes. Analyses were performed using R with both fixed-effect and random-effects models. Results: Nine RCTs (804 patients) were included in the analysis. Therapeutic comparisons revealed no differences in mean arterial pressure between NE and ephedrine (SMD = 0.51, 95% CI: −0.49, 1.53) or phenylephrine and ephedrine (SMD = 0.90, 95% CI: −0.01, 1.82). Phenylephrine was associated with a significantly higher risk of bradycardia compared to ephedrine (OR = 14.34, 95% CI: 1.8, 113.64, P = 0.018), whereas NE showed an insignificant difference (OR = 2.54, 95% CI: 0.27, 23.94). NE significantly improved the umbilical artery pH compared to ephedrine (SMD = 0.32, 95% CI: 0.02, 0.62, P = 0.036). No significant differences were identified in nausea or vomiting. Prophylactic comparisons revealed no significant differences between phenylephrine and NE for hypotension (OR = 0.98, 95% CI: 0.22, 4.26). For bradycardia, no difference was observed between NE and ephedrine (OR = 0.08, 95% CI: 0.002, 3.33) or phenylephrine and ephedrine (OR = 0.19, 95% CI: 0.006, 74). Conclusions: Phenylephrine, ephedrine, and NE exhibit comparable haemodynamic effects and maternal side effects, although phenylephrine increases the risk of bradycardia. NE improves umbilical artery pH.
No takes yet. Share an insight, caveat, or question.
Badran et al. (2025) conducted a meta-analysis in Pre-eclampsia with spinal-induced hypotension (n=804). Phenylephrine vs. Ephedrine was evaluated on Maternal incidence of bradycardia (OR 14.34, 95% CI 1.8, 113.64, p=0.018). Phenylephrine significantly increased the risk of maternal bradycardia compared to ephedrine (OR 14.34) in pre-eclamptic patients undergoing caesarean section.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: